Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sara Wasilenko

Vascular Surgery Olympia, WA Doctor of Osteopathy

NPI 1528387941 CMS profile 24324

128 Lilly Rd Ne Ste 205, Olympia, WA 98506

Open in the dashboard

General payments

$6,600

67 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sara Wasilenko of Olympia, WA is reported in the CMS Open Payments database as having received $6,600 across 67 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $862 9
2024 General $270 5
2023 General $4,999 36
2022 General $170 5
2021 General $183 5
2020 General $50 3
2019 General $66 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sara Wasilenko
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Sara Wasilenko were reported at $862. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Sara Wasilenko Vascular Surgery median Middle half National median
2019 $66 $796 $226–$2,363 $163
2020 $50 $348 $118–$1,110 $114
2021 $183 $471 $158–$1,421 $132
2022 $170 $725 $222–$2,183 $149
2023 $4,999 $836 $257–$2,440 $160
2024 $270 $909 $252–$2,619 $164
2025 $862 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $3,666 30 payments
  2. Penumbra, Inc. $1,863 9 payments
  3. Medtronic, Inc. $310 10 payments
  4. Cook Medical LLC $306 4 payments
  5. Abiomed $117 1 payment
  6. Amgen Inc. $98 1 payment
  7. Silk Road Medical, Inc. $68 2 payments
  8. Medtronic Vascular, Inc. $53 3 payments
  9. LeMaitre Vascular, Inc. $40 2 payments
  10. Boston Scientific Corporation $37 2 payments
  11. Other $45 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,775 12 payments
  2. Food and Beverage $2,825 55 payments
Products named General payments · program years 2019–2025
  1. Indigo System $1,837 8 payments
  2. GORE TAG Thoracic Endoprosthesis $1,146 5 payments
  3. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $854 8 payments
  4. GORE TAG Conformable Thoracic Endoprosthesis $658 4 payments
  5. GORE TAG Thoracic Branch Endoprosthesis $559 6 payments
  6. GORE TAG Conformable Thoracic Stent Graft $347 4 payments
  7. ENDURANT IIS $182 8 payments
  8. Impella $117 1 payment
  9. Zilver PTX $108 1 payment
  10. ONYX FRONTIER $104 1 payment
  11. Other $891 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

144

Median for Vascular Surgery: 122

Drug cost

$7,501

Median for Vascular Surgery: $14,135

Branded share of claims

91.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 11 $6,699
Clopidogrel Clopidogrel Bisulfate Brand 109 $708
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $49
Oxycodone Hcl Generic 12 $46

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 96 billing codes

Paid by Medicare

$157,068

Medicare's payments for the services billed

Medicare patients

522

Average age 75

Services billed

1,272

249 women, 273 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 43%
Diabetes 39%
Chronic kidney disease 37%
Heart failure 30%
Atrial fibrillation 30%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

67 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record